...

CCO Independent Conference Coverage

American Society of Hematology 2008 Annual Meeting*

December 6-9, 2008 | San Francisco, California

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Acute Leukemias/Myelodysplastic Syndromes

Track 1 of 4
Capsule Summaries
Expert Analysis
CCO Expert Recap
CCO Slideset

Program Director: Roy A. Beveridge, MD

Faculty:

Hagop M. Kantarjian, MDAlan F. List, MDMartin S. Tallman, MD
  • Hagop M. Kantarjian, MD
  • Alan F. List, MD
  • Martin S. Tallman, MD
Robert S. Mocharnuk, MD
  • Robert S. Mocharnuk, MD

Chronic Lymphocytic Leukemia/Chronic Myeloid Leukemia

Track 2 of 4
Capsule Summaries
Expert Analysis

Program Director: Roy A. Beveridge, MD

Faculty:

Brian Druker, MDKanti Rai, MDWilliam G. Wierda, MD, PhD
  • Brian Druker, MD
  • Kanti Rai, MD
  • William G. Wierda, MD, PhD
Allen S. Yang, MD, PhD
  • Allen S. Yang, MD, PhD

Lymphomas

Track 3 of 4
Capsule Summaries
Expert Analysis
CCO Expert Recap
CCO Slideset

CME Program Director: Roy A. Beveridge, MD

Faculty:

Steven H. Bernstein, MDOwen A. O'Connor, MD, PhDJulie M. Vose, MD
  • Steven H. Bernstein, MD
  • Owen A. O'Connor, MD, PhD
  • Julie M. Vose, MD
Peter J. Rosen, MD
  • Peter J. Rosen, MD

Multiple Myeloma/Plasma Cell Disorders

Track 4 of 4
Capsule Summaries
Expert Analysis
CCO Expert Recap
CCO Slideset

Program Director: Roy A. Beveridge, MD

Faculty:

William I. Bensinger, MDSagar Lonial, MDPaul G. Richardson, MD
  • William I. Bensinger, MD
  • Sagar Lonial, MD
  • Paul G. Richardson, MD
Edward A. Stadtmauer, MD
  • Edward A. Stadtmauer, MD

Other Studies of Interest


Expert Viewpoint:

Howard Liebman, MD, reviews current thinking regarding idiopathic thrombocytopenic purpura, including studies presented at the 2008 hematology meeting.


Capsule Summaries:

Erythropoiesis Stimulating Agents - ESAs

Idiopathic Thrombocytopenic Purpura - ITP


Expert Highlights

Updates in CLL

Now Playing...

Kanti Rai, MD, discusses updates in CLL therapies, including lenalidomide in the frontline setting, FCR data from the REACH trial, and the novel agent ofatumumab.


 

Mouse over thumbnails for more information on the segments
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Capsule Summary:

Combination of CMC-544 and Rituximab Produces High Response Rates in Relapsed FL and DLBCL Patients

Inotuzumab ozogamicin added to rituximab produces high response rates in patients with relapsed FL and DLBCL in a phase I/II trial

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES